Subcutaneous administration of paracetamol—Good local tolerability in palliative care patients: An observational study

Abstract

Background:

The subcutaneous route is widely used in both palliative care and geriatrics. Numerous compounds are administered by this route, including paracetamol. However, there is no recommendation on which to base this latter practice and, in the absence of published evidence, nothing is known regarding its local tolerability in palliative care patients.

Aim:

The main objective of this study was to assess the local tolerability of paracetamol when administered subcutaneously for analgesic or antipyretic purposes in patients hospitalized in the palliative care unit. The secondary objective was to identify the factors favoring the occurrence of local adverse events.

Design:

This is a prospective multicenter observational study (NCT02884609).

Participants:

Study conducted in 160 patients hospitalized in the palliative care units of three hospitals in metropolitan France from 2014 to 2017.

Results:

Of the 160 patients, 44 (28%) presented at least one non-serious local adverse event (edema in 29, erythema in 5, pain in 15, hematoma in 2, pruritus in 1, and local heat in 2). No serious adverse events were observed. Factors associated with the occurrence of local adverse events were younger age, administration in the arm and thorax, and a high number of daily administrations.

Conclusion:

This first ever study carried out on this subject reveals that subcutaneous administration of paracetamol in palliative care patients was well tolerated locally.

Keywords

Acetaminophen drug-related side effects and adverse reactions palliative medicine observational study

Get full access to this article

View all access options for this article.

References

Morisson

Vassal

Rochas

et al . Drugs used subcutaneously in palliative care: review of the literature and recommendations. Méd Palliat 2012; 11(1): 39–49.

Fonzo-Christe

Vukasovic

Wasilewski-Rasca

et al . Subcutaneous administration of drugs in the elderly: survey of practice and systematic literature review. Palliat Med 2005; 19(3): 208–219.

Picon

Duwig

Administration des médicaments par voie sous-cutanée; une alternative intéressante en gériatrie. Repères en Gériatrie 2011; 13(109): 143–146.

Graham

Syringe drivers and subcutaneous sites: a review. Eur J Palliat Care 2006; 13(4): 138–141.

Masson

Leheup

BF.

Use of subcutaneous acetaminophen in palliative care unit in France. Méd Palliat 2018; 17(1): 3–9.

Graham

Scott

Day

RO.

Tolerability of paracetamol. Drug Saf 2005; 28(3): 227–240.

Bannwarth

Péhourcq

Pharmacologic basis for using paracetamol: pharmacokinetic and pharmacodynamic issues. Drugs 2003; 63(2): 5–13.

Tremblay Nguyen

Noublanche

Barre

et al . Pain management in elderly people. La Revue De Gériatrie 2012; 37(3): 173–183.

Pickering

Pain, opioïds and the elderly. Cah Année Gérontol 2014; 6: 21–25.

10.

Claudot

Alla

Fresson

et al . Ethics and observational studies in medical research: various rules in a common framework. Int J Epidemiol 2009; 38(4): 1104–1108.

11.

Rat

Jouve

Pickering

et al . Validation of an acute pain-behavior scale for older persons with inability to communicate verbally: Algoplus. Eur J Pain 2011; 15(2): 198.e1–198.e10.

12.

Bruera

Legris

Kuehn

et al . Hypodermoclysis for the administration of fluids and narcotic analgesics in patients with advanced cancer. J Pain Symptom Manag 1990; 5(4): 218–220.

13.

Walker

Watanabe

Lawlor

et al . Subcutaneous clodronate: a study evaluating efficacy in hypercalcemia of malignancy and local toxicity. Ann Oncol 1997; 8(9): 915–916.

14.

Thomas

Yocum

Haller

et al . The INFUSE-Morphine IIB study: use of recombinant human hyaluronidase (rHuPH20) to enhance the absorption of subcutaneous morphine in healthy volunteers. J Pain Symptom Manag 2009; 38(5): 673–682.

15.

Barbot

Venisse

Rayeh

et al . Pharmacokinetics and pharmacodynamics of sequential intravenous and subcutaneous teicoplanin in critically ill patients without vasopressors. Intensive Care Med 2003; 29(9): 1528–1534.

16.

Hardy

Quinn

Fazekas

et al . Randomized, double-blind, placebo-controlled study to assess the efficacy and toxicity of subcutaneous ketamine in the management of cancer pain. J Clin Oncol 2012; 30(29): 3611–3617.

17.

Maison

Gastine

Peter-Derex

et al . Subcutaneous administration of levetiracetam in geriatrics. Rev Neurol (Paris) 2015; 171(4): 398–399.

18.

Lopez-Saca

Vaquero

Larumbe

et al . Repeated use of subcutaneous levetiracetam in a palliative care patient. J Pain Symptom Manag 2013; 45(5): e7–8.

19.

Adams

Cruz

Deachman

et al . Focal subdermal toxicity with subcutaneous opioid infusion in patients with cancer pain. J Pain Symptom Manag 1989; 4(1): 31–33.

20.

Cools

Berkhout

De Bock

GH.

Subcutaneous morphine infusion by syringe driver for terminally ill patients. Age Ageing 1996; 25(3): 206–208.

21.

Taillandier

Manigand

Fixy

et al . Skin necrosis induced by subcutaneous gentamicin. Presse Med 1984; 13(25): 1574–1575.

22.

Bricaire

Castaing

Pocidao

et al . Pharmacokinetics and tolerance of ceftriaxone after subcutaneous administration. Pathol Biol 1988; 36(5): 702–705.

23.

Forestier

Gros

Peynaud

et al . Ertapenem administered intravenously or subcutaneously for urinary tract infections caused by ESBL producing Enterobacteriaceae. Med Maladies Infect 2012; 42(9): 440–443.

24.

Bartz

Klein

Seifert

et al . Subcutaneous administration of drugs in palliative care: results of a systematic observational study. J Pain Symptom Manag 2014; 48(4): 540–547.

25.

Nikles

Mitchell

Hardy

et al . Single-patient multiple crossover studies to determine the effectiveness of paracetamol in relieving pain suffered by patients with advanced cancer taking regular opioids: a pilot study. Palliat Med 2016; 30(8): 800–802.

26.

Nabal

Librada

Redondo

et al . The role of paracetamol and nonsteroidal anti-inflammatory drugs in addition to WHO Step III opioids in the control of pain in advanced cancer. Palliat Med 2012; 26(4): 305–312.

27.

Israel

Parker

Charles

et al . Lack of benefit from paracetamol (acetaminophen) for palliative cancer patients requiring high-dose strong opioids: a randomized, double-blind, placebo-controlled, crossover trial. J Pain Symptom Manage 2010; 39(3): 548–554.

28.

Mercadante

Giarratano

The long and winding road of non steroidal antinflammatory drugs and paracetamol in cancer pain management: a critical review. Crit Rev Oncol Hemat 2013; 87(2): 140–145.